MedTrace Logo

A Pragmatic Approach to Lower Diabetes Risk After Gestational Diabetes

NCT05280496 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2025-04-20

No results posted yet for this study

Summary

This study is testing whether daily metformin for 1 year postpartum can reduce risk of diabetes in patients who had gestational diabetes. Typical care for prediabetes after gestational diabetes is counseling on diet and lifestyle. This study is researching whether management of diabetes prevention is more effective with the drug metformin. This study will be conducted at Tufts Medical Center.

Conditions

  • Diabetes, Gestational
  • PreDiabetes
  • Diabetes Mellitus, Type 2

Interventions

DRUG

Metformin

Metformin is used to lower blood sugar in patients with high blood sugar (diabetes).

Sponsors & Collaborators

  • Tufts Medical Center

    lead OTHER

Principal Investigators

  • Erika Werner, MD · Tufts Medical Center

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-01
Primary Completion
2025-03-01
Completion
2025-04-18
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05280496 on ClinicalTrials.gov